Quantification of diffuse myocardial fibrosis by cardiac magnetic resonance imaging

Quantification of diffuse myocardial fibrosis by cardiac magnetic resonance imaging - Fibrosis CMR

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006225

Enrollment

110

Registered

2014-06-17

Start date

2013-01-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: Tissue characterization by CMR using T1-mapping. These data will be compared with biopsies taken during heart catheterization.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: = 18 years old informed consent Symptoms of heart failure (NYHA>1) Transthoracic echocardiography: LVEF>50% LVEDVI15 15>E/e’>8 and NT-proBNP >220pg/ml

Exclusion criteria

Exclusion criteria: 1. Unwillingness to participate 2. LVEF<50% 3. Significant valvular lesion 4. Congenital heart disease 5. Significant coronary artery disease 6. Diastolic dysfunction without symptoms of heart failure 7. Severe renal impairment (GFR<30ml/min) 8. Pregnancy 9. Asthma bronchiale or COPD with a FEV1<60% 10. Restrictive lung disease with a total lung capacity <60% 11. Severe abnormalities of thorax, lungs or diaphragm 12. Severe abnormalities in blood gas analysis: SaO2<88% or PaO2<55mmHg

Design outcomes

Primary

Measure	Time frame
Quantification of diffuse myocardial fibrosis by CMR using T1-mapping will be compared with biopsies taken during heart catheterization.	—

Countries

Austria

Contacts

Public ContactJulia Mascherbauer

Medizinische Universität WienUniversitätsklinik für Innere Medizin IIAbteilung für Kardiologie

julia.mascherbauer@meduniwien.ac.at43 1 40400 46140

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026